Partner Headlines - CPHD

  1. Morning Market Gainers

    Benzinga
  2. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga
  3. Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

    Benzinga
  4. Leading Medical Stock Cepheid Trying To Break Out

    IBD
  5. Benzinga's Top Upgrades

    Benzinga
  6. Bank of America Upgrades Cepheid To Buy

    Benzinga
  7. UPDATE: Citigroup Reiterates On Cepheid Following Positive Data

    Benzinga
  8. Top Medical Stocks: Cepheid Diagnostics Sales Strong

    IBD
  9. Cepheid Receives FDA Clearance For Xpert Norovirus, The First ...

    Benzinga
  10. CEPHEID

    IBD
  11. Cepheid Receives FDA Clearance For Xpert Flu/RSV XC

    Benzinga
  12. Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

    Benzinga
  13. Several Sectors Emerge As Leaders Of New Market Uptrend

    IBD
  14. Stocks Fight Back To Finish Mixed

    IBD
  15. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
  16. Cepheid Explores Test For Ebola Disease; Q3 Beats

    IBD
  17. CEPHEID

    IBD
  18. Cepheid Extends Reach Of Direct US Commercial Operations

    Benzinga
  19. UPDATE: ISI Group Upgrades Cepheid

    Benzinga
  20. CEPHEID

    IBD
  21. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  22. Alexion Takes Off On Outlook

    IBD
  23. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  24. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  25. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market ...

    Benzinga
  26. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  27. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  28. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining ...

    Benzinga
  29. Benzinga's Top Downgrades

    Benzinga
  30. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  31. Benzinga's Top Downgrades

    Benzinga
  32. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' ...

    Benzinga
  33. Cepheid Announces Board of Directors Changes

    Benzinga
  34. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate ...

    Benzinga
  35. Medtech Stocks Moving As Conference Makes Waves

    IBD
  36. Medtech Stocks Moving As Conference Makes Waves

    IBD
  37. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ...

    Benzinga
  38. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  39. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on ...

    Benzinga
  40. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  41. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  42. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  43. Stocks To Watch For December 28, 2012

    Benzinga
  44. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  45. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, ...

    Benzinga
  46. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  47. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of ...

    Benzinga
  48. Benzinga's Top Downgrades

    Benzinga
  49. Benzinga's Top Upgrades

    Benzinga
  50. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  51. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst ...

    Benzinga
  52. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 ...

    Benzinga
  53. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  54. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst ...

    Benzinga
  55. Benzinga Mid-Afternoon Market Update

    Benzinga
  56. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  57. Benzinga Mid-Day Market Update

    Benzinga
  58. Mid-Morning Market Update

    Benzinga
  59. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative ...

    Benzinga
  60. Benzinga's Top Initiations

    Benzinga
  61. A Peek Into The Market Before The Trading Starts

    Benzinga
  62. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  63. Benzinga's Top Initiations

    Benzinga
  64. Technology Sector Wrap

    FoxBusiness
  65. Technology Sector Wrap

    FoxBusiness
  66. Technology Sector Wrap

    FoxBusiness
  67. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  68. Cepheid Down 20% on Weak Guidance

    Benzinga
  69. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
  70. CEPHEID (CPHD) CEO John L Bishop sells 25,000 Shares

    GuruFocus
  71. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 17,437 Shares

    GuruFocus
  72. A Peek Into The Market Before The Trading Starts

    Benzinga
  73. UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic ...

    Benzinga
  74. Benzinga's Top Downgrades With Color for May 14, 2012

    Benzinga
  75. UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; ...

    Benzinga
  76. Cepheid Earnings Miss Estimates; Stock Plummets

    IBD
  77. Cepheid Q1 Estimates Soft, But Outlook For Year Good

    IBD
  78. Zoll Deal, Intutive Surgical Lift Medical Equipment

    IBD
  79. Cepheid Stock Price Rises on Strong 2012 Sales Outlook

    IBD
  80. CEPHEID Reports Operating Results (10-K)

    GuruFocus
  81. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 62,062 Shares

    GuruFocus
  82. CEPHEID (CPHD) CEO John L Bishop sells 6,887 Shares

    GuruFocus
  83. CEPHEID (CPHD) Executive VP, COO Humberto Reyes sells 133,957 ...

    GuruFocus
  84. Stocks Finish Week Split; Nasdaq, S&P 500 Higher

    IBD
  85. Stocks Stay Mixed; Under Armour Clears 50-Day

    IBD
  86. RBC Capital Upgrades Cepheid to Outperform

    Benzinga
  87. UPDATE: Credit Suisse Initiates Outperform, $40 Target on Cepheid

    Benzinga
  88. Analogic Earnings Preview: EPS Expected to Double

    Benzinga
Trading Center